Labcorp (LH) CFO awarded new stock options and 2,350 RSUs

Rhea-AI Filing Summary

Labcorp Holdings Inc. chief financial officer Julia Aijun Wang received new equity awards. On February 10, 2026, she was granted 7,100 non-qualified stock options with an exercise price of $284.50 per share and 2,350 restricted stock units.

The options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036. The restricted stock units also vest in three equal annual installments beginning on February 10, 2027, with each unit delivering one share of Labcorp common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wang Julia Aijun

Role Chief Financial Officer, EVP

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	7,100	$0.00	--
Grant/Award	Restricted Stock Unit	2,350	$0.00	--

Holdings After Transaction: Non-qualified Stock Options — 7,100 shares (Direct); Restricted Stock Unit — 5,824 shares (Direct)

Footnotes (1)

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The option vests in three equal annual installments beginning on the date reflected in this column. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Julia Aijun

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer, EVP

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Options(1)	$284.5	02/10/2026		A		7,100		02/10/2027(2)	02/09/2036	Common Stock	7,100	$0	7,100	D
Restricted Stock Unit	(3)	02/10/2026		A		2,350		(4)	(4)	Common Stock	2,350	$0	5,824(5)	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Julia Aijun Wang	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Labcorp (LH) grant to its CFO on February 10, 2026?

Labcorp granted CFO Julia Aijun Wang 7,100 non-qualified stock options and 2,350 restricted stock units. These awards provide long-term equity incentives tied to Labcorp’s share price and future service-based vesting conditions over multiple years.

How do Julia Aijun Wang’s new stock options from Labcorp (LH) vest and when do they expire?

The 7,100 non-qualified stock options vest in three equal annual installments starting on the February 10, 2026 grant date. They remain exercisable until February 9, 2036, giving a long window to convert vested options into Labcorp common shares.

What are the key terms of the restricted stock units Labcorp (LH) awarded to its CFO?

Labcorp awarded 2,350 restricted stock units, each representing the right to receive one share of common stock. These units vest in three equal annual installments beginning on February 10, 2027, aligning executive compensation with long-term shareholder outcomes.

Under which compensation plan were Labcorp (LH) stock options granted to the CFO?

The employee stock options were granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. This plan authorizes equity-based awards, such as options and restricted stock units, to align executive and employee incentives with the company’s long-term performance.

What is the exercise price of the new Labcorp (LH) stock options granted to the CFO?

The non-qualified stock options have an exercise price of $284.50 per share. This means Julia Aijun Wang can purchase Labcorp common stock at that price for vested options any time before the options’ February 9, 2036 expiration date.

How many Labcorp (LH) restricted stock units does the CFO hold after the reported grant?

After the February 10, 2026 grant of 2,350 units, the reporting shows 5,824 restricted stock units held. This aggregate figure reflects the total number of unvested restricted stock units beneficially owned by the executive at that time.